CD8A and neoplasm: In a previous study, we had already shown in BalbC mice grafted with KLN205 cells that the combination of anti-VEGF and the pemetrexed/cisplatin doublet led to an optimal remodeling of tumor immunity in a time-dependent manner, i.e., by best increasing the T CD8/Tregs ratio 2 weeks after administration, suggesting that sequential treatments with immunotherapy might be of interest, although at that time no efficacy study was performed to test this hypothesis[23].